NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...

Ivana Magovčević-Liebisch President and CEO, Dr Magovčević-Liebisch is an accomplished pharmaceutical and biotechnology ...

Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in biobucks for inhibitors aimed at a red-hot inflammation target. | Neurocrine ...

New research reveals how tiny electrical gates in the brain, known as NMDA receptors, control learning, memory, and neuron ...

The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - The primary endpoint was met with 76% of participants administered ...

Pharma announced positive topline results from CALIBRATE, its global Phase 3 study of encaleret in autosomal dominant ...

A systematic review published today in Psychedelics by Mr. James Gattuso and colleagues at the Florey Institute of Neuroscience and Mental Health synthesizes clinical and preclinical evidence on ...

Tempero Bio has hit the brakes on a phase 2-stage alcohol use disorder (AUD) candidate while the biotech considers its ...

Researchers used supramolecular nanoparticles to repair the brain’s vascular system and reverse Alzheimer’s in mice. Instead ...

A new medication for treatment-resistant depression may help a subset of people who carry a specific genetic marker.